Two pharmaceutical companies, Biogen and Ionis, have announced the termination of their experimental treatment for ALS, also known as Lou Gehrig's disease. The decision comes after the treatments failed to show improvement in patients during an early to mid-stage study.
This development represents a significant setback in the ongoing search for new therapies for ALS, a rare neurodegenerative disorder that affects the voluntary control of limbs and can lead to breathing difficulties. It is estimated that most patients diagnosed with ALS succumb to the disease within five years of onset.
